Revolutionary Transplant Test Sets New Standard with Unparalleled Accuracy
Insight Molecular Diagnostics unveils a groundbreaking test at the World Transplant Congress, nearly doubling industry accuracy standards.
NASHVILLE, Tenn., July 30, 2025 (GLOBE NEWSWIRE) – Insight Molecular Diagnostics (iMDx) has announced a revolutionary advancement in the medical field, revealed at the World Transplant Congress in San Francisco. Their novel test displays an exceptional ability to detect organ rejection with an accuracy level previously unseen, nearly doubling the industry standard.
An Innovative Approach Sets a New Benchmark
iMDx introduced the world to their cutting-edge dd-PCR assay, which uniquely combines both relative and absolute measurements of donor-derived cell-free DNA (dd-cfDNA) into a single combined score. This innovative approach achieves a positive predictive value (PPV) of 79% for graft rejection, a significant leap from the average 48% seen in previous methodologies.
Bridging Clinical Applications and Technological Advancements
The breakthrough dd-cfDNA combined score broadens the clinical utility by reducing false positives and, importantly, minimizing unnecessary invasive biopsies. According to Stock Titan, it paves the way for wider adoption in clinical practice, enhancing decision-making and care for transplant patients.
Unprecedented Reliability and Utility
“The dual utility of dd-cfDNA tests could transform the diagnostic landscape by reliably ruling in as well as ruling out transplant rejection,” explained Prof. Dr. Ekkehard Schuetz, Chief Science Officer at iMDx. His sentiments were echoed by CEO Josh Riggs, who emphasized the importance of precision in diagnostics and applauded the team’s success in reaching these new heights.
Looking Ahead: Broader Implications for Healthcare
iMDx aims to evaluate this combined assay score through ongoing FDA studies. Their GraftAssure product line, featuring the GraftAssureCore and GraftAssureIQ assays, demonstrates the impactful convergence of research innovation and practical application. As the landscape of transplant medicine evolves, iMDx remains at the forefront, shaping the future of noninvasive rejection prediction.
Shaping the Future of Transplant Diagnostics
As noted in their closing plenary at the Congress, dd-cfDNA has emerged as the leading tool for noninvasive discrimination of organ rejection, offering dynamic injury assessment. This marks a monumental step not only for iMDx but for the field of transplant medicine worldwide, reaffirming dd-cfDNA’s place as a critical asset in post-transplant care.
The integration of iMDx’s innovative assays within medical practices promises to enhance patient outcomes, standing as a testament to the transformative power of precision medicine.
